Electrostatic potential on human leukocyte antigen: implications for putative mechanism of chronic beryllium disease. by Snyder, James A et al.
Chronic beryllium disease (CBD) is a
seriously debilitating, life-threatening occu-
pational disease that occurs primarily
among workers engaged in beryllium (Be)
extraction and puriﬁcation and preparation
of Be metal and its alloys (Kolanz 2001;
Powers 1991). High-risk, high-exposure job
categories include machining and ceramics
production (Kreiss et al. 1997). In addition,
certain downstream users are also known to
be at risk, for example, dental technicians
who ﬁle or grind prostheses containing Be
alloy (OSHA 2002). In addition, Be deliv-
ered on clothing or contaminated motor
vehicles could constitute a risk to family
members not actually employed in the Be
industry (Sanderson et al. 1999).
CBD is generally recognized to be
preceded by immunologic sensitization to
the metal, a phenomenon shared with con-
ditions related to a number of metals like
gold, silver, nickel, vanadium, cobalt,
chromium, and copper (Budinger and
Hertl 2000; Lawrence and McCabe 2002).
Skin sensitization to Be (BeS) was recog-
nized 50 years ago, and a Be-lymphocyte
proliferation test (BeLPT) was developed in
the 1970s. Surveillance programs, using the
BeLPT, identify approximately 10% of Be
workers who are not symptomatic but who
are sensitized. Be-sensitized individuals
may progress to CBD, and approximately
2–5% of all Be workers develop CBD
(Maier 2001).
The recognition that CBD appeared to
affect a subset of exposed workers and
included an immunologic component sug-
gested a genetic basis for susceptibility to
BeS and CBD. Anti–human leukocyte
antigen (HLA) antibodies blocked the Be-
specific proliferation response in lympho-
cytes of workers sensitized to Be (Saltini
et al. 1989). Subsequently, a molecular epi-
demiologic study implicated HLA-DPB1
encoding a glutamic acid in position 69 of
the mature protein with susceptibility to
CBD (Richeldi et al. 1993).
Recent studies have confirmed that
genetic susceptibility to CBD involves
HLA glycoproteins, T-cell receptor clonal-
ity, and have suggested the involvement of
tumor necrosis factor polymorphisms
(Tinkle et al. 2003). These HLA glyco-
proteins are heterodimers comprising an α-
chain and a β-chain, which form an
antigen-binding moiety. Binding of the
antigen occurs in an elongated groove on
the surface of this complex (Figure 1). The
ﬂoor of the groove is composed of β-sheets,
and the walls of α-helices (Li et al. 2000).
By September 2003, 106 different
HLA-DPB1 alleles had been described, 65
encoding lysine (K) at codon 69, 5 encod-
ing arginine (R), and 36 encoding glutamic
acid (E) (EBI 2003; Marsh 2003). Data
from molecular epidemiologic studies that
used high-resolution allele-specific DNA-
sequencing technology preliminarily sug-
gest an HLA-DPB1 allele hierarchy (Wang
et al. 1999). Although numbers of study
subjects are small, we have hypothesized
that inheritance of certain alleles conveys
more risk than others, with the following
order: HLA-DPB1*1701 (most risk) >
*0601 > *0901 = *1001 > *1301 >
*1901 = *0201 > *0401 (Rossman et al.
2002; Saltini et al. 2001; Tinkle et al.
2003; Wang et al. 1999, 2001).
To investigate the basis for the
suggested interindividual genetic suscepti-
bility to CBD, we constructed three-dimen-
sional structural models of HLA-DP
representing several distinct allotypes and
calculated the electrostatic potential on the
surface of these models. The allotypes were
predicated upon two types of α-chain
sequences and five types of β-chain
sequences. The α-chain sequences encoded
by HLA-DPA1*0103 and *0201 alleles, and
β-chains encoded by HLA-DPB1*1701,
*0201, *1901, *1301, and *0401 alleles
were selected, allowing for 10 possible
analytic models.
Materials and Methods
Molecular Modeling
There are no experimentally determined
coordinates for HLA-DP in the Protein
Data Bank (PDB; http://www.rcsb.org/
pdb/). We modeled the extracellular part
of HLA-DP by homology to a known
HLA species. Overall, the primary, sec-
ondary, and tertiary structure in the class
II family of major histocompatability com-
plex (MHC) is well conserved. We have
selected one HLA-DR, PDB entry 1FV1
(HLA-DRA*0101/B5*0101; Li et al. 2000)
as a template. Our choice was based on a
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Toxicogenomics Articlerelatively good resolution of the template
compared with other HLA entries (1.90 Å,
R-factor = 0.233), the total number of
crystallographically resolved residues, and
the results of a sequence alignment using
the GCG program (Accelrys, Inc., San
Diego, CA).
The SYBYL 6.6 molecular modeling
software (Tripos, Inc., St. Louis, MO) was
used to make modifications to the HLA-
DR template. It was first necessary to
repair several residues in the template, in
which coordinates of some side-chain (SC)
atoms were missing. Next, speciﬁc SC sub-
stitutions were introduced, which con-
verted the sequence of HLA-DR protein to
that of HLA-DP. The deletion of two
residues in the gap required reconstruction
of one loop region. After addition of all
hydrogen atoms, positions of the selected
SC atoms and the backbone (BB) of the
engineered loop were subjected to 50 itera-
tions of the steepest descent minimization,
followed by an exhaustive minimization
using the Powell method (Powell 1977),
until the full convergence by the energy
gradient was reached. For minimization,
the Kollman all-atom force field (Weiner
et al. 1984) with distance-dependent
dielectric and a cutoff radius of 10 Å was
used. All BB and Cβ (except proline Cβ)
atoms were held ﬁxed by treating them as a
rigid body aggregate. Stereochemical qual-
ity of the HLA-DP model was tested using
the WHATIF program (Vriend 1990).
Modeled coordinate sets are available from
the authors upon request.
Electrostatic Calculations
The electrostatic potential was calculated
using the DelPhi module of the Insight II
program (Accelrys). Insight II was also used
to generate the isopotential surface maps.
The electrostatic potential was calculated
by numerically solving the linearized
Poisson-Boltzmann equation using a ﬁnite
difference method. The low-dielectric
macromolecule (protein interior) was
embedded in a high-dielectric continuum
environment (water exterior). A solution
with charged ions was simulated having an
assigned ionic strength of 0.145, which
typifies conditions at the physiologic pH.
Using an ionic radius of 2.0 Å for the sol-
vated ions, a Stern layer was constructed
around the solvent-accessible surface, hav-
ing a null ionic strength inside, which
determines the maximum distance that an
ion can approach the solvent-accessible sur-
face. The assigned temperature was 298 K.
The resulting system was discretized on a
grid, and the potential at the grid points
was solved iteratively starting from the
Debye-Hückel boundary conditions. To
improve the accuracy of calculated poten-
tials, we used a method of grid focusing.
This involved three additional calculations
in which the molecule was allowed to
occupy a successively larger fraction of the
cubic grid volume so that values of the
potential at the grid boundary could be cal-
culated using the larger grid from each pre-
ceding calculation. The grid dimensions
were selected to be 1,200 Å (spacing
4 Å/grid point), 600 Å (spacing 2 Å/grid
point), 300 Å (spacing 1 Å/grid point), and
100 Å (spacing 0.75 Å/grid point). The
interior and exterior dielectric constants
were 4 and 80, respectively. The solute
boundary was deﬁned by a solvent-accessi-
ble surface generated by a rolling probe
sphere of 1.4 Å radius. Partial atomic
charges and radii were taken from the
PARSE (Sitkoff et al. 1994) parameter set,
which was originally optimized for proteins
by fitting the solvation free energies of
amino acid analogs.
Estimation of the Odds of Adverse
Health Outcome Associated with
Speciﬁc HLA-DPB1 Haplotypes 
in Beryllium Workers
It was suggested that susceptibility to CBD
conferred by different HLA-DPB1*E69
haplotypes is not equal. In Be-exposed
workers inheritance of certain HLA-
DPB1*E69 haplotypes might convey
greater susceptibility than others (Wang
et al. 1999). Initially, we examined the data
they reported and attempted to deduce
allele-specific risk estimates (McCanlies
et al. 2003; Tinkle et al. 2003). Because
the number of cases was small (n = 20), we
further pooled these data with data from
several more-recent studies (Rossman et al.
2002; Saltini et al. 2001; Wang et al.
2001). A simple allelic hierarchy was devel-
oped based on the proportional allelic fre-
quencies reported for CBD, Be-sensitized,
and controls. Odds ratios (ORs) were cal-
culated using the Mantel-Haenzel estimate
(SAS Institute, Inc. 1999) of the common
relative risk for each allele (HLA-
DPB1*0201, *0401, *0601, *0901, *1001,
*1301, *1601, *1701, and *1901) by ana-
lyzing each study population individually
and by pooling data from all studies. 
Results
In this study we investigated a putative link
between electrostatic properties of
HLA-DP allotypes and corresponding ORs
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Figure 1. Class II MHC antigen-binding pocket. Model shown is for the HLA-DPA1*01031/B1*1701 genotype.of epidemiologically observed susceptibility
to CBD. The molecular electrostatic
potential (MEP) represents the electrostatic
properties of a molecule, quantum-
mechanical effects notwithstanding.
Stretching around the molecule, the MEP
comprehensively describes intermolecular
electrostatic interactions, which often have
a signiﬁcant impact on ligand binding. 
The electrostatic potential around the
extracellular part of the HLA-DP protein
was calculated using computer-generated
homology models of HLA-DP allotypes.
The calculations were performed in the
absence of antigenic peptides, which for
HLA-DP are not yet known. Further, these
calculations did not take into account the
phospholipid membrane responsible for
anchoring the protein. Because the anti-
gen-binding groove and the transmem-
brane domain of class II MHC are located
a relatively large distance apart (approxi-
mately 60 Å) at the opposite ends of the
extracellular part of the complex, the effect
of the membrane on the electrostatic
potential in the vicinity of the binding
groove was assumed to be similar in differ-
ent HLA-DP allotypes. Thus, the present
analysis focuses on the distinctions
in electrostatic potential on different
HLA-DP allotypes.
The homology models of HLA-DP
allotypes were generated from the X-ray
coordinate set of the HLA-DR protein,
Brookhaven code 1FV1. The amino acid
sequence alignments between the corre-
sponding chains of 1FV1 and HLA-DP are
shown in Figure 2. The sequence align-
ment yielded approximately 64% identity
in a 181 amino acid overlap between
1FV1A and the HLA-DPA1 sequences,
and 65% identity in a 190 amino acid
residue overlap between 1FV1B and the
HLA-DPB1 sequences. There was a single
two-residue gap in the alignment of
β-chains, beginning at position 24, and
there were no gaps at all in the alignment
of the α-chains. Overall, the results of
sequence analysis indicate a high homology
between the three-dimensional structure of
1FV1 and HLA-DP. Usually, the high
structural homology between two protein
species implies an unequivocal reconstruc-
tion of unknown species from the coordi-
nates of a known template.
Further validation of the derived struc-
tural models was conducted using the
WHATIF program (Vriend 1990), and the
coordinates of homology models were sub-
jected to a number of quality control tests.
To predict the probabilistic likelihood for
the particular rotamer of a given SC in the
model, the distribution of the χ1 torsion
angles of the model was compared with a
distribution of rotamers in the WHATIF
database. Scores between 0 and 1 were
computed, in which a value close to 1
implies high likelihood for that rotamer. A
histogram of the scores collected for all
residues in both the α- and β-chains is pre-
sented in Figure 3. In general, for most
crystal structures subjected to this test, less
than 10% of residues have scores lower
than 0.4. Only three residues in the
α-chain scored below 0.4, and there were
no scores in any of the chains lower than
0.3. These results agree with expectations
arising from a comprehensive analysis of
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*01031 IKADHVSTYAAFVQTHRPTGEFMFEFDEDEMFYVDLDKKETVWHLEEFGQAFSFEAQGGLANI
1FV1α IKEEHVIIQAEFYLNPDQSGEFMFDFDGDEIFHVDMAKKETVWRLEEFGRFASFEAQGALANI
10        20        30        40        50        60
*01031 AILNNNLNTLIQRSNHTQATNDPPEVTVFPKEPVELGQPNTLICHIDKFFPPVLNVTWLCNGE
1FV1α AVDKANLEIMTKRSNYTPITNVPPEVTVLTNSPVELREPNVLICFIDKFTPPVVNVTWLRNGK
70        80        90       100       110       120
*01031 LVTEGVAESLFLPRTDYSFHKFHYLTFVPSAEDFYDCRVEHWGLDQPLLKHWEAQ
1FV1α PVTTGVSETVFLPREDHLFRKFHYLPFLPSTEDVYDCRVEHWGLDEPLLKHWEFD
130       140       150       160       170
B
*1701  RATPENYVHQLRQECYAFNGTQR--FLERYIYNREEFVRFDSDVGEFRAVTE
1FV1β GDTRPRFLQQDKYECHFFNGTERVRFLHRDIYNQEEDLRFDSDVGEYRAVTE
10        20        30        40        50
*1701  LGRPDEDYWNSQKDILEEERAVPDRMCRHNYELDEAVTLQRRVQPKVNVSPS
1FV1β LGRPDAEYWNSQKDFLEDRRAAVDTYCRHNYGVGESFTVQRRVEPKVTVYPA
60        70        80        90       100
*1701  KKGPLQHHNLLVCHVTDFYPGSIQVRWFLNGQEETAGVVSTNLIRNGDWTFQ
1FV1β RTQTLQHHNLLVCSVNGFYPGSIEVRWFRNSQEEKAGVVSTGLIQNGDWTFQ
110       120       130       140       150
*1701  ILVMLEMTPQQGDVYICQVEHTSLDSPVTVEWKAQSDSAQSKTLTG
1FV1β TLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRA
160       170       180       190
Figure 2. Sequence alignment of (A) HLA-DPA1*0103 with α-chain of HLA-DR2 (PDB: 1FV1A) and (B) of
HLA-DPB1*1701 with β-chain of HLA-DR2 (PDB: 1FV1B). Residues in bold indicate mismatches.
Figure 3. Histogram of WHATIF scores for rotamer check of α- and β-chains of HLA-DPA1*0103/B1*1701
model. Bin = 0.01 
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communication).
An additional WHATIF check
involved looking at the ﬁne-packing quality
for both the homology model for HLA-
DPA1*0103/B1*1701 and the 1FV1 pro-
tein. Quality control values for individual
residues are intended to measure the ﬁt of a
residue in the particular part of the struc-
ture. If the z-score for the protein is greater
than –2.5 (2.5 standard deviations less than
the mean), then the structure is acceptable
or good. A z-score less than –3 suggests
that the structure likely is poor. For all
BB-SC contacts, the z-scores were –2.78
for the 1FV1 protein, and –2.87 for the
model structure. For all BB-BB contacts,
the z-scores were 0.38 and 0.62 for 1FV1
and model, respectively. It appears that
reconstruction of the loop region in the
model produced an improvement in qual-
ity with respect to BB-BB contacts, as this
was the only modiﬁcation made to the BB
of the 1FV1 template. The z-scores for all
types of contacts (BB-BB, BB-SC, SC-BB,
and SC-SC) were –1.52 and –1.27 for the
1FV1 and model, respectively, indicating
an overall improvement in the packing
quality for the homology model compared
with the template.
As a final WHATIF check, a torsion
angle evaluation was performed. The com-
puted scores indicate, for each residue, how
normal the torsion angles are, as described
by normality scores using all torsion angles
except ω. Average values and standard devi-
ations are extracted from residues in the
WHATIF database and used to compute z-
scores. A residue with a z-score less than
–2.0 is poor, indicating that more than one
torsional angle is in a highly unlikely posi-
tion. For 1FV1, a total of 5 residues (3 in
the α-chain and 2 in the β-chain) were
listed as poor. For the HLA-DPA1*0103/
B1*1701 model, a total of seven residuals
were listed as suspicious (2 in the α-chain
and 5 in the β-chain). Residues having for-
bidden ϕ-ψ combinations are listed, along
with residuals with unusual ω angles, which
are angles that deviate by more than 3σ
from the normal value. It is typical to ﬁnd
that approximately 5% of the residues in a
structure have unusual ϕ-ψ combinations.
There were 17 residues (out of 369 in the
structure) listed with poor scores for the
1FV1 protein, and 22 residues (out of 367
in the structure) listed for the model. The
χ1/χ2 correlation z-score indicates the qual-
ity of correlation between χ1 and χ2 angles.
Both values are considered acceptable.
Thus, all quality control tests performed on
the structures indicate a high likelihood of
the derived homology model.
The initial assessment of electrostatics-
related effects was carried out using the pri-
mary structures of HLA-DP allotypes.
Figure 4 represents the amino acid sequence
alignments of commonly found HLA-DP
alleles. Epidemiologic studies have not pro-
vided convincing evidence for an associa-
tion between and susceptibility to CBD of
α-chain alleles of HLA-DP (Figure 4A).
Nevertheless, they are required for recon-
struction of the three-dimensional structure
of the extracellular part of MHC class II
complex. Some β-chain alleles have also
been surveyed. Figure 4B represents the
β-chain alleles for which epidemiologic
association data were available at the time
of the study.
Except for the residue α50 (Figure 4A),
all substitutions involving ionizable residues
are conﬁned in a relatively short stretch of
the β-chain alignment (Figure 4B). These
are residues β55–β56, β69, and β84–85.
From the analysis of the three-dimensional
model, it appears that all residues involved
in the substitutions affecting the charge are
spatially adjacent to the groove (Figure 1).
Table 1 lists the total charge on the β-
chains encoded by the HLA-DPB1 alleles.
The variation in total charge between the
different alleles is determined by the pres-
ence of acidic (–1) or basic (+1) substitu-
tions in the three aforementioned regions.
For example, comparing *0401 and *1701
allotypes, the substitution of Asp β55, Glu
β56, Asp β84, and Glu β85 for Ala β55,
Ala β56, Gly β84, and Gly β85 produces a
difference of –4e, and substitution of Glu
β69 for Lys β69 contributes a –2e differ-
ence, making *1701 six units more nega-
tive than *0401. HLA-DPB1*1701, *1601,
*1001, *0901, and *0601 contain similarly
charged residues in the three regions. Thus,
all these β-chains carry the same total
charge, and the results for other alleles
belonging to this group are expected to be
similar. Only one of these β-chains, *1701,
was used in this study.
In Table 1 the β-chain alleles are
partitioned in four groups based on the
total charge on the chain (column 2).
Grouping β-chain alleles by charge in this
way provides for a more robust statistical
analysis. The ORs for either CBD or BeS
Toxicogenomics | Snyder et al.
1830 VOLUME 111 | NUMBER 15 | November 2003 • Environmental Health Perspectives
A
*02011                               Q                  R
*01031 IKADHVSTYAAFVQTHRPTGEFMFEFDEDEMFYVDLDKKETVWHLEEFGQAFSFEAQGGLANI
10        20        30        40        50        60
*02011                    A                           R      
*01031 AILNNNLNTLIQRSNHTQATNDPPEVTVFPKEPVELGQPNTLICHIDKFFPPVLNVTWLCNGE
70        80        90       100       110       120
*02011 P                                V
*01031 LVTEGVAESLFLPRTDYSFHKFHYLTFVPSAEDFYDCRVEHWGLDQPLLKHWEAQ
130       140       150       160       170       180
B
*0401        LF G                        A
*1301         Y                         YA
*02012       LF G
*1901        LF G
*1701 RATPENYVHQLRQECYAFNGTQRFLERYIYNREEFVRFDSDVGEFRAVTE
10        20        30        40        50
*0401     AAE           K GGPM        R
*1301     AAE                  I
*02012      E                          GGPM        R
*1901     EAE                  I
*1701 LGRPDEDYWNSQKDILEEERAVPDRMCRHNYELDEAVTLQRRVQPKVNVSPS
60        70        80        90       100
*0401
*1301
*02012
*1901
*1701 KKGPLQHHNLLVCHVTDFYPGSIQVRWFLNGQEETAGVVSTNLIRNGDWTFQ
110       120       130       140       150
*0401                T
*1301
*02012               T
*1901
*1701 ILVMLEMTPQQGDVYICQVEHTSLDSPVTVEWKAQSDSAQSKTLTG
160       170       180       190       200
Figure 4. Sequence alignment of (A) HLA-DPA1*0103 with HLA-DPA1*0201 and (B) HLA-DPB1*1701 with
HLA-DPB1*1901, *0201, *1301, and *0401. Underlined residues represent substitutions that contribute a
change in sign of charge depending on the identity of the residue in that position.are reported in columns 6 and 7, respec-
tively. The highest estimates of ORs for
CBD were found consistently in β-chain
alleles coding for isotypes that carry the
greatest negative charge. Conversely, the
lowest ORs for CBD were associated with
alleles coding for the least negatively
charged HLA-DPB1*0401 (K69) isotype.
HLA-DPB1*1901 and *0201 and *1301
carry intermediate negative charge, and
they also were associated with intermediate
ORs for CBD. Overall, there seems to be
an obvious link between the amount of
negative charge on the β-chain and corre-
sponding ORs for CBD.
The highest ORs for BeS were also
found in β-chain alleles that code for iso-
types carrying the greatest negative charge.
Comparison of these ORs with ORs asso-
ciated with less negatively charged iso-
types also indicates a likely possibility of
connection between the charge and ORs.
However, in the case of BeS, the picture is
masked by the HLA-DPB1*1901 allele,
whose OR disrupts the otherwise regular
rank order in column 7. At present we do
not have a comprehensive explanation for
this observation, except that it may be the
result of a small number of observations.
The epidemiologic basis for the calculated
*1901 OR in BeS is one reported case; this
is reﬂected in large, overlapping conﬁdence
intervals (CIs) calculated for this allele. In
addition, the deviation may be caused by
interference of unknown α-chains (see
below), which have not been reported in
the source studies.
It is evident from the table that the
ORs have an approximately log-linear rela-
tionship to the magnitude of negative
charge on the β-chain of HLA-DP.
Figure 5 shows fits of ungrouped log-ORs
using the log-linear regression. The vari-
ance-covariance matrix analysis suggests
that log-ORs for both CBD and BeS are
reasonably well correlated with the charge.
The correlation coefficients are –0.85 and
–0.67, respectively. As the data are natu-
rally stratified by charge, we further broke
the matrix into lack-of-fit and pure-error
terms. The lack-of-fit term represents the
deviation of fitted values from group
means, i.e., it characterizes the quality of
the ﬁt. The pure-error term speciﬁes a scat-
ter of the data around the means, which is
the statistical noise that interferes with the
regression. The lack-of-fit test indicated a
statistically representative fitting with log-
linear regression of both the CBD and BeS
data. The calculated test-statistic numbers
F2,5 were 0.16 and 1.04, respectively, indi-
cating that the null hypothesis for a poor ﬁt
could not be accepted even at the 60%
level. A fairly large scatter of the data
within the groups, which is seen in
Figure 5, is due to the limited data avail-
able for individual alleles. The coefficients
of determination, which measure the ran-
dom scatter, were 0.71 and 0.45 for the
CBD and BeS regressions, respectively.
Despite this, both regressions were statisti-
cally significant according to the standard
test for the zero slope of regression line
(F1,7 are 17.51 and 5.68, respectively).
Thus, we conclude that the analyzed epi-
demiologic association data support the
hypothesis of an association between the
charge on an allele and observed ORs for
both CBD and BeS.
To more effectively analyze how the
charge distribution varies among HLA-DP
proteins, we calculated the electrostatic
potential on the solvent-accessible surface
of each protein. Figure 6 illustrates the
locations of the three regions, which
according to Table 1 determine the varia-
tion of charge on the β-chain. Each of the
three regions is located in proximity to the
peptide-binding groove. Figure 6A and B
compare the electrostatic potential at the
solvent-accessible surface of HLA-DP allo-
types involving the least and one of the
most negatively charged β-chain alleles.
They are HLA-DPA1*0103/B1*0401 and
HLA-DPA1*0103/B1*1701, respectively.
These maps clearly show intensification of
negative potential in the binding-groove
region of the protein encoded by *1701
allele compared with that encoded by
*0401. In addition to the solvent-accessible
potential surface maps, which show how
the potential varies along the surface
drafted by the centers of the rolling probe
sphere (e.g., the ion), it is also useful to
analyze the MEP on the protein, which is
given by the isopotential surface maps.
Figure 7 illustrates the MEP at a contour
level of –2 kT/e (red) and +2 kT/e (blue)
for HLA-DPA1*0103/B1*0401, *0201,
*1301, and *1701, respectively. The MEPs
on HLA-DPA1*0103/B1*1301, *1901 and
*1701 are compared in Figure 8, in which
the view is rotated by 90° to analyze the
effect of the substitution in position β56.
Variations of MEP in other parts of the
protein are fairly minor, as the substitu-
tions of charged residue are conﬁned to the
binding groove only.
Comparison of MEPs in Figures 6–8
shows how the potential surface is altered
by the amino acid substitutions, and hence,
the charge in the regions β55–β56, β69,
and β84–β85. In the case of the *0401
protein (Figure 7A), in which the β-chain
does not carry any negatively charged
residues in positions β55, β56, β84, and
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Table 1. Total charge of the β-chain encoded by HLA-DPB1 alleles and ORs based on grouping data by
charge.
Total charge CBD ORb BeS ORc
HLA-DPB1 on β-chaina β55, β56 β69 β84, β85 (95% CI) (95% CI)
*1701 D E E D E
*1601 D E E D E
*1001 –9 D E E D E 6.5 (3.5–11.9) 5.3 (3.0–9.3)
*0901 D E E D E
*0601 D E E D E
*1901 –8 E A E D E 4.2 (0.9–19.0) 1.2 (0.1-10.5)
*1301 A A E D E
*0201 –7 D E E G G 2.1 (1.3–3.3) 2.2 (1.5–3.4)
*0401 –3 A A K G G 0.5 (0.3–0.9) 0.7 (0.4–1.1)
CI, conﬁdence interval. 
aThe charge on each allotype was determined under an assumption of standard pKa values for all ionizable residues. It
implies that at the physiological pH, the residues adopt fully ionized states, i.e., aspartate and glutamate each carry a
charge of –1e, and arginine and lysine carry a charge of +1e. Histidine and cysteine residues were assumed to be neu-
tral. bORs calculated from pooled data reported by Rossman et al. (2002), Saltini et al. (2001), and Wang et al. (1999, 2001).
cCould not be deduced from Wang et al. (1999, 2001).
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Figure 5. Statistical odds of (A) conferring CBD and (B) BeS versus formal charge on the β-chain of HLA
allotypes.β85, there is virtually no appearance of
negative MEP in the peptide-binding
groove region. Instead, the central part of
the groove is occupied by a stretch of posi-
tive MEP, which is due to a positively
charged Lys β69. Figure 7B illustrates how
substitutions for negatively charged
residues in positions β55, β56, and β69
induce negative MEP in the binding
groove of the *0201 protein. Similarly,
Figure 7C shows the emergence of negative
MEP resulting from substitutions for nega-
tive residues in the positions β69, β84, and
β85 of the *1301 protein. Comparison of
Figure 7B and C indicates how much Glu
β69 contributes to the negative MEP on
allotypes involving the *0201 and *1301
alleles. Figure 7D demonstrates a situation
in which negatively charged residues are
substituted for all residues constituting the
three genetic marker regions. When
Figure 7B–D is compared, we can see that
the substitutions in the three regions result
in a roughly additive increase of the surface
of negative MEP in and around the groove.
In the future, in-depth quantitative analysis
will be applied to determine the magnitude
of negative MEP inside the groove.
However, the shape of negative MEP
around Glu β69 in Figure 7D is apparently
enlarged compared with Figure 7B and C,
probably originating from the increased
negativity of MEP inside the groove. If this
is the case, it may partially explain the link
between charge and ORs reported in
Table 1 and Figure 5. 
The effects of replacing Ala β55 in the
*1301 protein with Glu β55 in the *1901
protein and replacing both Ala β55 and
Ala β56 with negatively charged residues in
the *1701 protein are illustrated in
Figure 8. Similar to Figure 7, substitution
for charged residues results in a corre-
sponding appearance of increasingly more
negative MEP. All studied HLA-DP
β-chain proteins contain either an Asp or
Glu residue in the position β57, which
itself influences the shape and magnitude
of MEP in this region. For example, there
is a Glu in position β57 in the *0201
protein, whereas the *1701 protein has an
Asp in this position. Evidently, the pres-
ence of Glu or Asp in this position affects
the appearance of the negative MEP
around the region of β56, β57, as can be
seen by examining Figure 7B and D (or
Figure 9A and B, described below). 
The total charge on the α-chain
encoded by HLA-DPA1*0201 is –17, and
it is –18 on HLA-DPA1*0103. The replace-
ment of Gln50 in the α-chain encoded by
HLA-DPA1*0103 with Arg50 encoded by
HLA-DPA1*0201 imparts one additional
unit of positive charge. The MEP on two
HLA-DP allotypes involving the *0201
allele of the α-chain is shown in Figure 9.
The figure represents homology models of
HLA-DPA1*0201/HLA-DPB1*1701 and
HLA-DPA1*0201/HLA-DPB1*0201.
These should be compared with Figures 7B
and 7D, which are for HLA-DPA1*0103/
HLA-DPB1*1701 and HLA-DPA1*0103/
HLA-DPB1*0201, respectively. Comparison
of these two pairs shows that the effect of
adding one additional unit of positive
charge on the α-chain can be deduced in
the absence (Figures 7B and 9A) and pres-
ence (Figures 7D and 9B) of negative
charge in the β84–β85 region of the
β-chain. The Q50R substitution in the
α-chain causes a profound effect on the
MEP in the immediate vicinity of α50.
However, it is not clear how much this
substitution affects the MEP inside the
groove. Conversely, unlike β69, this
residue is located at the very edge of the
peptide-binding groove, and thus its effect
on the binding may be fairly small.
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Figure 6. Electrostatic potential surface maps for the binding groove. (A) HLA-DPA1*0103/B1*0401. (B) HLA-DPA1*0103/B1*1701. The scale indicates color-coded
values of the electrostatic potential (kT/e). The surface is a solvent-accessible surface generated as described in the text. The wire frame denotes a putative
location of the antigen as it is given by the 1FV1 template.
B
ASP β55
GLU β57
GLU β56 GLU β69
GLY β84
GLY β85
GLN α50
A
ALA β56
ALA β55
LYS β69
GLY β84
GLY β85
GLN α50
ALA β55
GLN α50
GLU β85
ASP β84
GLU β69
ALA β56
C D
ASP β55
ASP β57
GLU β56
GLU β69
ASP β84
GLU β85
GLN α50
Figure 7. Isopotential surface maps for the binding groove region. (A) HLA-DPA1*0103/B1*0401. (B) *0201.
(C) *1301. (D) *1701. Red and blue represent contours at –2 and +2 kT/e, respectively. The isopotential sur-
face map is superimposed on the solvent-accessible surface (shown in white), so that only a part of the
isopotential surface that lies on or above the solvent-accessible surface is visible. The wire frame
denotes a putative location of the antigen as it is given by the 1FV1 template.Alternatively, the other two important
markers of the β-chain, β55–β56 and
β84–β85, are similarly distant from the
center of the groove as α50. From Figures
8 and 9, we already know that the effect of
substituting different residues in one par-
ticular region can, to some extent, alter
MEP in an adjacent region. Additional epi-
demiologic studies may help to clarify the
role of α-chain substitutions in the etiology
of CBD. From a structural point of view
we do not see obstacles to interference with
binding from yet unknown substitutions in
the α-chain. Alternatively, if such substitu-
tions indeed do not affect ligand binding,
additional computational investigations are
needed to explain the physiologic differ-
ences between substitutions in the α- and
β-chains.
Discussion
Occupational or environmental exposures
to metals may cause severe health disorders
related to modulation of immune home-
ostasis. Metal immunomodulation has been
implicated in chronic inflammatory
processes, autoimmune diseases, and related
adverse effects (Cunningham-Rundles et al.
2000; Lawrence and McCabe 2002).
Molecular mechanisms of immunological
actions of metals are largely unknown. In
this work we explored a possible link
between molecular properties of genetic
products conferring susceptibility to Be and
the health effects of Be exposures. The
results of this work are useful for interpret-
ing the molecular recognition in MHC
class II proteins and for investigating their
interactions with Be2+. Previous studies
have suggested Glu β69 as an important
genetic marker for conferring susceptibility
to CBD (Díaz et al. 1998; Fontenot et al.
2000; Lombardi et al. 2001; Potolicchio
et al. 1999; Richeldi et al. 1993, 1997;
Rossman et al. 2002; Saltini et al. 2001;
Wang et al. 1999, 2001). More recent stud-
ies have led some investigators to suggest
that the charged residues Asp β55 and Glu
β56 might also contribute to the recogni-
tion of HLA-DP by T cells (Díaz et al.
1998; Fontenot et al. 2000; Potolicchio et
al. 1999). In a study of the binding of
cobalt to HLA-DP, Potolicchio et al.
(1999) compared the binding affinity for
cobalt by HLA-DPB1*0201 (which has Asp
β55, Glu β56, and Glu β69) and by HLA-
DPB1*0402 (which has Asp β55, Glu β56,
and Lys β69), and also by HLA-
DPB1*0401 (which has Ala β55, Ala β56,
and Lys β69). They found that the binding
afﬁnity for radioactive 57Co2+ decreased in
the order HLA-DPB1*0201 > HLA-
DPB1*0402 > HLA-DPB1*0401, conﬁrm-
ing earlier evidence for involvement of
Glu β69 but also suggesting that positions
β55 and β56 may also be involved in the
interaction. A similar study with HLA-
DPB1*0101 and HLA-DPB1*0401, which
both carry Ala β55, Ala β56, and Lys β69,
failed to present Be2+ to CD4+ T cells,
whereas HLA-DPB1*0202 and other alleles
with Glu β55, Asp β56, and Glu β69 were
positive for presentation of Be2+ to T cells
(Fontenot et al. 2000). 
In this study the electrostatic potential
on model proteins encoded by several HLA-
DPA1 and HLA-DPB1 alleles was analyzed.
The genetic polymorphisms in different
alleles are responsible for substitutions of
charged residues (Glu, Asp, Arg, Lys) in
positions 55–56, 69, and 84–85 of the
amino acid sequence of the β-chain
(Figure 1). We found a clear correlation
between the total charge on protein variants
and epidemiologic odds ratios conferring
susceptibility to either BeS or CBD. The
MEP contours in Figures 7 and 8 illustrate
the distribution of charge in the three sig-
niﬁcant regions in proximity to the binding
groove. Hence, HLA-DPA1*0103/B1*1701,
which carries the most negative charge, also
appears to confer the greatest susceptibility
for BeS and CBD. We appreciate that in all
cases of HLA-DPB1 alleles coding for glu-
tamic acid in position 69, the 95% confi-
dence intervals overlap. This stems from the
lack of sufﬁcient power of the studies, both
independently and together, to answer the
question of allele-specific risk hierarchy.
However, given the consistency of the dif-
ferent studies, the data strongly suggest that
such a hierarchy exists.
Originally, we examined data reported
by Wang et al. (1999) and were able, to a
limited extent, to account for homozygos-
ity. The analyses presented here do not
account for the impact of homozygosity
versus heterozygosity. Moreover, we are
unaware of the impact of any potential
allele misclassification, which is suggested
by the growing numbers of haplotypes
reported since 1999. Regarding the rank-
ing of alleles with respect to BeS (Table 1),
we considered the possibility of bias,
potentially introduced by the data
reported by Saltini et al. (2001), as, unlike
those of Wang et al. (2001) and Rossman
et al. (2002), these data did not show
an association between inheritance of
Toxicogenomics | Electrostatic potential on HLA-DP
Environmental Health Perspectives • VOLUME 111 | NUMBER 15 | November 2003 1833
ALA β55 ALA β56
B
GLU β56 ASP β55
C
ALA β56 ALA β55
A
Figure 8. Isopotential surface maps for the binding groove region. (A) HLA-DPA1*0103/B1*1301. (B) *1901. (C) *1701. Red and blue represent contours at –2 and +2
kT/e, respectively. The solvent-accessible surface is displayed in white. The wire frame denotes a putative location of the antigen as it is given by the 1FV1 template.
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Figure 9. Isopotential surface maps for the binding groove region. (A) HLA-DPA1*0201/B1*0201. (B) HLA-
DPA1*0201/B1*1701. Red and blue represent contours at –2 and +2 kT/e, respectively. The solvent-acces-
sible surface is shown in white. The wire frame denotes a putative location of the antigen as it is given by
the 1FV1 template.HLA-DPB1*E69 and BeS. However, elim-
ination of the BeS data reported by Saltini
et al. (2001) from our analyses did not
change the overall ranking.
All of the reports described were
case–control studies, and we remain igno-
rant of many facets of the natural history of
CBD, especially as it pertains to the pro-
gression from BeS to disease. In addition,
diagnosis of BeS remains problematic. It
may be that a relatively high OR associated
with CBD but a relatively low allele-spe-
cific OR associated with BeS reflects a
greater propensity for progression from BeS
to CBD (e.g., as may be the case for HLA-
DPB1*1001).
As Figure 5 illustrates, there appears to
be a log-linear relationship between ORs
and charge on the protein. Although an
improved set of data may alter the fit, it
is noteworthy that such a relationship
exists, as it suggests that this kind of analy-
sis may be useful for eventually predicting
disease susceptibility for new allotypes for
which epidemiologic data are lacking
or unavailable.
As far as the molecular mechanism of
CBD is concerned, a previous study has
indicated that Be2+ may bind in the vicinity
of Glu β69, perhaps directly in the peptide-
binding groove (Amicosante et al. 2001). In
this connection the log-linear dependence
of the odds ratios (essentially the probability
expressed in the units of background) on
the charge is curious because it resembles
the Boltzmann distribution in a two-site
charge–charge interaction model when all
other parameters are fixed. At present, we
are unaware whether it is a coincidence or
fact reﬂecting a yet unknown peculiar mode
of ion binding. This puzzle may be resolved
in future studies, which will shed additional
light on the molecular mechanisms of
metal-dependent immunomodulation.
Conclusion
Our results complement recent findings,
which implicate positions β55, β56, β69,
β84, and β85 of HLA-DPB1 in suscepti-
bility to CBD. This approach may prove
useful in predicting risk associated with
previously unknown alleles and may help
lead to the elucidation of mechanistic
issues associated with CBD. Further studies
will be directed at identifying the beryllium
binding site on the HLA-DP protein.
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